24/7 Market News Snapshot 03 June, 2025 – ReShape Lifesciences, Inc. Common Stock (NASDAQ:RSLS)

June 3, 2025

DENVER, Colo., 03 June, 2025 (www.247marketnews.com) – (NASDAQ:RSLS) are discussed in this article.
ReShape Lifesciences, Inc. (RSLS) is experiencing a notable surge in the pre-market session, with shares trading at $8.296, reflecting a remarkable increase of 92.48% from the previous close of $4.310. The trading volume soared to approximately 3.96 million shares, indicating an enthusiastic response from investors and substantial market interest in the company’s innovative health solutions. This significant price movement suggests a potential momentum shift for RSLS, capturing the attention of traders who may see this as an advantageous opportunity to harness the company’s growth potential.

In parallel, ReShape Lifesciences has achieved a critical regulatory milestone with the successful certification of its Quality Management System and medical devices under the European Union Medical Device Regulation (MDR) and the United Kingdom Conformity Assessment (UKCA). This positions ReShape among a few manufacturers who meet the stringent compliance standards required in these key markets. The MDR introduces enhanced safety and quality requirements, while the UKCA has replaced the CE mark for products entering the UK market, both ensuring the highest acceptable standards for patients.

Paul F. Hickey, President and CEO, underscores the importance of this certification, pointing out that achieving MDR and UKCA compliance before the December 31, 2027 deadline reflects ReShape’s commitment to excellence and innovation. This accomplishment not only broadens their reach to 30 countries in Europe but also strengthens their capabilities in expanding their product pipeline.

Dov Gal, Vice President of Regulatory, Quality, and Clinical Affairs, noted the potential challenges many legacy devices face in receiving timely certification, which could lead to market shortages. He reaffirmed the company’s dedication to providing consistent availability of their innovative devices, thereby ensuring safety and performance excellence. With an array of solutions aimed at combating obesity, including the FDA-approved Lap-Band® System, ReShape Lifesciences is well-positioned for sustained growth and increased market presence.

Related news for (RSLS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.